This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

POSTER ABSTRACT SUBMISSION DEADLINE:

  • 00
    DAYS
  • 00
    HRS
  • 00
    MINS
  • 00
    SECS
Delivered as a Hybrid Event from December 12 - 16, 2021
Live In-Person Experience Delivered December 12 - 16 2021Marriott Marquis San Diego

Marina Roell
Principal Scientist, Antibody Discovery and Protein Engineering at Alector

Profile

Marina Roell is a Principal Scientist in Antibody Discovery and Protein Engineering at Alector, where she contributes to a mission to translate genetic insights into therapeutics that leverage the immune system to cure neurodegeneration and cancer. After receiving her PhD in Biochemistry and Molecular Biology at UC Santa Barbara and completing an NIH Postdoc at UC Berkeley, she moved to Bayer Corporation, where she began her focus on Therapeutic Antibody Discovery and SPR-based protein interaction analysis. She was responsible for implementing phage display technology and integrating SPR binding analyses into the screening and characterization of therapeutic antibodies at Bayer, DiaDexus, and XOMA. In addition to providing analysis of binding kinetics for protein-protein interactions, a major focus has been to use SPR to accelerate identification of functional antibodies and to elucidate molecular mechanism of action. She contributed to the engineering of the anti-IL1β clinical candidate, gevokizumab, and was responsible for identifying its non-competitive, kinetic modulating mechanism through SPR experiments. Dr. Roell is an inventor on multiple patents and applications, including therapeutic antibodies, phage library design to facilitate biophysical screening, and methods to screen for kinetic-modulating drugs. She has contributed to the discovery and engineering of multiple therapeutic antibodies that were advanced into clinical development or licensed for further development, including an anti-IL2 antibody that drives differential receptor activation of T-cell subsets. In her current role she leads the Molecular Interactions function to screen and characterize antibodies, antigens, and related proteins, and employs the Carterra LSA for high-throughput parallel analysis of antibodies to targets involved in neurodegeneration and oncology.

Agenda Sessions

  • MerTK Agonism and Antagonism: Patterns Revealed by Domain Binding Studies Using High Throughput Parallel SPR Analysis on the Carterra LSA

    1:15pm